Nicole Ferko
General Manager, Value and Evidence
Expertise:
Nicole directs U.S. and global projects to support multi-stakeholder medical device adoption and reimbursement. Nicole has more than 20 years of experience in health economics and research methods within academic, industry, and consulting roles. With her teams, she has successfully completed a wide range of project types including hospital value analysis briefs, market research surveys, economic sales tools, network meta-analyses, Delphi panels, and FDA clinical trial analyses. Nicole has co-authored more than 100 peer-reviewed publications including a book reflecting her area of expertise, entitled: The Science of Commerce: Succeeding in a Changed Medical Device Market. She has a broad therapeutic knowledge-base, having worked across several disease areas for biotechnology, pharmaceutical, and medical device products, including numerous medical device product types.
Nicole’s academic training includes a BSc in Biology and Pharmacology and an MSc in Health Research Methods, both from McMaster University.
Articles by Nicole Ferko
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
EVERSANA’s Value and Evidence (V&E) team grew their global Health Economics & Outcomes Research (HEOR) leadership footprint in early 2024 with the addition of Monique Martin, Pamela Vo and Deepika Thakur, showcasing EVERSANA’s growing global life sciences commercialization launch expertise. EVERSANA’s Value & Evidence team of ~150 seasoned HEOR researchers and industry experts are focused on […]
Excel in Market Access Success: Key Considerations for Leveraging Your Evidence
Introduction The landscape of launching new medical products presents significant challenges, with a staggering 66% of launches falling short of consensus expectations. Half of these failures are attributed directly to poor market access. Recognizing this, companies are increasingly turning to early engagement with payers during the clinical development phase to glean crucial insights into payer […]
Single-Arm Data: Turning Limitations into Strengths with Numbers
Randomized controlled trials (RCTs) are at the top of the evidence pyramid because they are designed to be unbiased. Unfortunately, for many medical devices, these types of studies are lacking. This is either because they are not required for 510K or post-market approval (PMA), or there are challenges with implementing a randomized study design. Clinical […]
ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer
APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:45-6:00 PM ET OBJECTIVES: Network meta-analyses (NMAs) generally include direct comparative evidence from randomized […]
ISPOR 2020 PANEL: Evidence Standards for Medical Device Adoption by U.S. Hospitals
ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL DEVICE ADOPTION BY U.S. HEALTHCARE PROVIDERS/HOSPITALS? Virtual ISPOR 2020 | MONDAY, May 18th, 2020 | 11:00 AM ET MODERATOR: Nicole Ferko, MSC, EVERSANA ISSUE: With cost containment pressures and the need to optimize health and healthcare delivery, U.S. healthcare providers/hospitals must consider economic value, in addition […]